Published in

Wiley, International Journal of Cancer, 1(154), p. 114-123, 2023

DOI: 10.1002/ijc.34701



Export citation

Search in Google Scholar

Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO


AbstractSevere calorie restriction, in the form of cyclic fasting or fasting‐mimicking diets (FMDs), boosts the antitumor activity of cytotoxic chemotherapy in mouse models of triple‐negative breast cancer (TNBC). This effect is mostly mediated by fasting/FMD‐induced reduction of plasma glucose concentration and by a boost in antitumor immunity. However, clinical evidence that cyclic FMD may impact on the outcomes of advanced TNBC (aTNBC) patients is lacking. We compared the overall survival (OS) of 14 aTNBC patients receiving first‐line carboplatin‐gemcitabine plus cyclic FMD in the context of the NCT03340935 trial with the OS of 76 consecutive aTNBC patients treated with carboplatin‐based chemotherapy alone at Fondazione IRCCS Istituto Nazionale dei Tumori. Multivariable Cox regression models were used to adjust the prognostic impact of FMD for other prognostic variables. Patients undergoing cyclic FMD in combination with carboplatin‐gemcitabine had better OS when compared to patients receiving chemotherapy alone (median OS 30.3 months, 95% CI 18‐NR, vs 17.2 months, 95% CI 15.3‐25.1, log‐rank P value .041). Multivariable analysis confirmed an association between FMD use and better OS (HR: 0.40; 95% CI: 0.19‐0.86; P = .019) also after propensity score‐based matching according to patient ECOG PS and the presence of de novo metastatic disease (HR: 0.41; 95% CI: 0.21‐0.83; P = .013). Cyclic FMD in combination with first‐line chemotherapy may improve clinical outcomes in aTNBC patients. Our study paves the way for conducting phase II trials to investigate if cyclic FMD can increase the antitumor activity/efficacy of chemotherapy or chemoimmunotherapy in patients with early‐stage TNBC or aTNBC.